Oregon Public Employees Retirement Fund Buys 10,482 Shares of Thermo Fisher Scientific Inc. $TMO

09 Jan 2026, 09:46 by Teresa Graham · The Cerbat Gem

Oregon Public Employees Retirement Fund increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 32.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 43,104 shares of the medical research company’s stock after buying an additional 10,482 shares during the quarter. Oregon Public Employees Retirement Fund’s holdings in Thermo Fisher Scientific were worth $20,906,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in TMO. CBIZ Investment Advisory Services LLC grew its holdings in Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock valued at $28,000 after purchasing an additional 33 shares during the last quarter. Highline Wealth Partners LLC boosted its position in shares of Thermo Fisher Scientific by 126.9% during the third quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after buying an additional 33 shares during the period. Anderson Financial Strategies LLC purchased a new stake in shares of Thermo Fisher Scientific in the first quarter worth approximately $30,000. Capital A Wealth Management LLC lifted its stake in shares of Thermo Fisher Scientific by 825.0% during the 2nd quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock worth $30,000 after acquiring an additional 66 shares during the last quarter. Finally, DiNuzzo Private Wealth Inc. grew its position in Thermo Fisher Scientific by 406.7% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 61 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on TMO. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, October 14th. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 25th. UBS Group lifted their price target on shares of Thermo Fisher Scientific from $500.00 to $590.00 and gave the company a “neutral” rating in a research note on Thursday, October 23rd. Leerink Partners raised their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a report on Wednesday, October 22nd. Finally, Argus upped their target price on Thermo Fisher Scientific from $580.00 to $610.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. One analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average price target of $621.70.

Read Our Latest Stock Analysis on Thermo Fisher Scientific

Thermo Fisher Scientific Stock Down 1.8%

Thermo Fisher Scientific stock opened at $606.16 on Friday. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $628.08. The business has a fifty day moving average of $580.33 and a two-hundred day moving average of $515.03. The firm has a market cap of $227.74 billion, a P/E ratio of 35.02, a P/E/G ratio of 4.06 and a beta of 0.91. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings data on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The firm had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same period in the prior year, the business posted $5.28 EPS. The firm’s quarterly revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Stockholders of record on Monday, December 15th will be given a $0.43 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its Board of Directors has approved a stock buyback plan on Thursday, November 6th that authorizes the company to repurchase $5.00 billion in shares. This repurchase authorization authorizes the medical research company to repurchase up to 2.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s leadership believes its stock is undervalued.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, COO Michel Lagarde sold 22,046 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $563.56, for a total value of $12,424,243.76. Following the completion of the sale, the chief operating officer directly owned 84,117 shares in the company, valued at $47,404,976.52. This trade represents a 20.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 7,250 shares of the company’s stock in a transaction on Monday, October 27th. The stock was sold at an average price of $566.10, for a total value of $4,104,225.00. Following the transaction, the chief executive officer directly owned 113,762 shares in the company, valued at approximately $64,400,668.20. The trade was a 5.99% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 149,271 shares of company stock valued at $86,507,282 over the last three months. Company insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.